Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indacaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 10/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | SRSF6 | Q13247 | 1/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indacaterol SCHEMBL29350045 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4186345 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29367297 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29798949 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL159597 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL867571 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL3664612 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012030 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL867570 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012026 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1010 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| US-20210236478-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2021-08-05 | — | — | US | claimed |
| EP-3191081-B1 | FORMULATION COMPRISING GLYCOPYRROLATE, METHOD AND APPARATUS | VECTURA LTD (GB) | 2020-03-25 | — | — | EP | claimed |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2019-09-19 | — | — | US | claimed |
| US-10227305-B2 | Process for preparing indacaterol and salts thereof | REDDY, G. Pratap (IN) | 2019-03-12 | — | — | US | claimed |
| US-20180215714-A1 | A Process for Preparing Indacaterol and Salts Thereof | REDDY, G. Pratap (IN) | 2018-08-02 | — | — | US | claimed |
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | claimed |
| EP-2978745-B1 | PROCESS FOR THE MANUFACTURE OF (R)-5-[2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-(1H)-QUINOLIN-2-ONE | LESVI LABORATORIOS SL (ES) | 2017-03-15 | — | — | EP | claimed |
| WO-2008000839-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | claimed |
| EP-1791820-A2 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | Novartis AG (CH) | 2007-06-06 | — | — | EP | claimed |
| US-20060252794-A1 | Process for preparing 5-'(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an andrenoceptor agonist | NOVARTIS AG (CH) | 2006-11-09 | — | — | US | claimed |
| JP-2006522055-A | — | — | 2006-09-28 | — | — | JP | claimed |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2006-08-24 | — | — | US | claimed |
| EP-1613599-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | Novartis AG (CH) | 2006-01-11 | — | — | EP | claimed |
| WO-2005123684-A2 | ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | claimed |
| EP-1599450-A1 | PROCESS FOR PREPARING 5-\"(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMIN O)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | Novartis AG (CH) | 2005-11-30 | — | — | EP | claimed |
| WO-2004087668-A1 | A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | claimed |
| WO-2004076422-A1 | PROCESS FOR PREPARING 5-‘(R)-2-(5,6-DIETHYL-INDIAN-2-YLAMINO)-1-HYDROXY-ETHYL!-8-HYDROXY-(1H)-QUINOLIN-2-ONE SALT, USEFUL AS AN ADRENOCEPTOR AGONIST | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215714-A1 | A Process for Preparing Indacaterol and Salts Thereof | CYP11B1, CYP4A11, CYP17A1 | ADRB2 181/4885ADRB1 109/4885SLC6A2 2324/4885 |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885SLC6A2 778/4885 |
| US-10227305-B2 | Process for preparing indacaterol and salts thereof | CYP4A11, HSD17B7, CYP17A1 | ADRB2 173/4885ADRB1 107/4885SLC6A2 1880/4885 |
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885SLC6A2 1034/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885SLC6A2 778/4885 |
| US-20210236478-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885SLC6A2 1020/4885 |
| US-20060252794-A1 | Process for preparing 5-'(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an andrenoceptor agonist | OPRL1, HTR5A, HTR7 | ADRB2 28/4885ADRB1 34/4885SLC6A2 138/4885 |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | UGT8, KAT8, UGT1A8 | ADRB2 632/4885ADRB1 757/4885SLC6A2 770/4885 |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 6/4885SLC6A2 987/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885SLC6A2 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.